Search results for "LSA"

showing 10 items of 832 documents

Bridging Mucosal Vessels Associated with Rhythmically Oscillating Blood Flow in Murine Colitis

2007

Oscillatory blood flow in the microcirculation is generally considered to be the result of cardiopulmonary influences or active vasomotion. In this report, we describe rhythmically oscillating blood flow in the bridging vessels of the mouse colon that appeared to be independent of known biological control mechanisms. Corrosion casting and scanning electron microscopy of the mouse colon demonstrated highly branched bridging vessels that connected the submucosal vessels with the mucosal plexus. Because of similar morphometric characteristics (19 +/- 11 microm vs. 28 +/- 16 microm), bridging arterioles and venules were distinguished by tracking fluorescent nanoparticles through the microcircul…

MalePathologymedicine.medical_specialtyHistologyPulsatile flowInflammationVasomotionMicrocirculationMiceImage Processing Computer-AssistedmedicineAnimalsIntestinal MucosaEcology Evolution Behavior and SystematicsMice Inbred BALB CPlexusChemistryMicrocirculationBlood flowColitisFlow velocityPulsatile FlowMicroscopy Electron ScanningBiophysicsAnatomymedicine.symptomBlood Flow VelocityIntravital microscopyBiotechnologyThe Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology
researchProduct

Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience

2010

This is the first multicenter Italian experience with rufinamide as an adjunctive drug in children, adolescents and adults with Lennox-Gastaut syndrome. The patients were enrolled in a prospective, add-on, open-label treatment study from 11 Italian centers for children and adolescent epilepsy care. Forty-three patients (26 males, 17 females), aged between 4 and 34 years (mean 15.9 ± 7.3, median 15.0), were treated with rufinamide for a mean period of 12.3 months (range 3-21 months). Twenty patients were diagnosed as cryptogenic and 23 as symptomatic. Rufinamide was added to the baseline therapy at the starting dose of 10mg/kg body weight, evenly divided in two daily doses and then increased…

MalePediatricsLennox-Gastaut syndromeAtypical absence seizuresRufinamideLennox–Gastaut syndrome; Rufinamide; Orphan drug; Pediatrics; Epilepsy; Drop attacksInfantilePediatricsSpasmsEpilepsyRufinamideDrop attacks; Epilepsy; Lennox-Gastaut syndrome; Orphan drug; Pediatrics; Rufinamide; Adolescent; Adult; Anticonvulsants; Child; Child Preschool; Drug Therapy Combination; Female; Humans; Intellectual Disability; Italy; Lennox Gastaut Syndrome; Male; Spasms Infantile; Treatment Outcome; Triazoles; Valproic Acid; Young Adult; Neurology (clinical); NeurologyChildPediatricValproic AcidDrop attacksGeneral MedicineSettore MED/39 - Neuropsichiatria InfantileTreatment OutcomeItalyNeurologyAnesthesiaChild PreschoolCombinationVomitingAnticonvulsantsDrug Therapy CombinationFemalemedicine.symptomSpasms Infantilemedicine.drugAdultmedicine.medical_specialtyAdolescentClinical NeurologyIrritabilityYoung AdultDrug TherapyIntellectual DisabilitymedicineHumanspediatrics epilepsyPreschoolAdverse effectLennox–Gastaut syndrome; rufinamide; orphan drug; pediatrics epilepsy; drop attacks; refractory epilepsy.EpilepsyOrphan drugbusiness.industryLennox Gastaut SyndromeValproic Acidrefractory epilepsyTriazolesmedicine.diseaseNeurology (clinical)businessLennox–Gastaut syndromeLennox–Gastaut syndrome
researchProduct

Survey on treatments for primary headaches in 13 specialized juvenile Headache Centers: The first multicenter Italian study

2017

Abstract Aim The purpose of this retrospective multicenter study was to evaluate the use and the self-perceived efficacy and tolerability of pharmacological and non-pharmacological treatments in children and adolescents with primary headaches. Methods Study of a cohort of children and adolescents diagnosed with primary headache, consecutively referred to 13 juvenile Italian Headache Centers. An ad hoc questionnaire was used for clinical data collection. Results Among 706 patients with primary headaches included in the study, 637 cases with a single type of headache (migraine 76% – with and without aura in 10% and 67% respectively; tension-type headache 24%) were selected (mean age at clinic…

MalePediatricsmedicine.medical_specialtyAdolescentMigraine DisordersAdolescents; Children; Migraine; Primary headaches; Tension-type headache; Treatment; Pediatrics Perinatology and Child Health; Neurology (clinical)Tension-typeTriptansPizotifenPediatrics03 medical and health sciences0302 clinical medicinechildrenPrimary headacheBehavior TherapySurveys and QuestionnairesmedicineAcupunctureHumansAmitriptylinemigraine030212 general & internal medicineadolescentsPractice Patterns Physicians'ChildFlunarizineRetrospective Studiestreatmentbusiness.industryAnti-Inflammatory Agents Non-SteroidalGeneral Medicineadolescents; children; migraine; primary headaches; tension-type headache; treatmentPerinatology and Child Healthmedicine.diseasetension-type headacheMigraineTolerabilityItalyPediatrics Perinatology and Child HealthCohortAnticonvulsantsFemaleprimary headachesNeurology (clinical)businessheadache030217 neurology & neurosurgeryPrimary headaches; Migraine; Tension-type; headache; Treatment; Children; Adolescentsmedicine.drug
researchProduct

Effects on executive functions of antiepileptic monotherapy in pediatric age.

2020

Abstract Objectives Cognitive abilities and executive functions in children and adolescents are important indicators of quality of life as well as academic and social achievements. Cognitive and executive functioning are often impaired in patients with epilepsy and can be exacerbated by seizures and antiseizure drugs. The aim of our observational retrospective study was to assess executive functioning in patients with pediatric epilepsy, currently taking a single antiseizure medication. Materials and methods Records of 172 children and adolescents aged between 6 and 18 years (mean age = 12 ± 3.4 years) with newly diagnosed epilepsy who had not yet commenced an antiepileptic treatment were i…

MalePediatricsmedicine.medical_specialtyLevetiracetamAdolescentAntiepileptic drugsOxcarbazepine03 medical and health sciencesBehavioral NeuroscienceEpilepsyExecutive Function0302 clinical medicinemedicineHumans030212 general & internal medicineOxcarbazepineChildChildrenRetrospective StudiesValproic AcidEpilepsybusiness.industrySeizure typesEpiTrack JuniorAge FactorsCarbamazepinemedicine.diseaseExecutive functionsTolerabilityCognitive functionsAntiepileptic drugs; Children; Cognitive functions; EpiTrack Junior; Executive function; TolerabilityCarbamazepineNeurologyTolerabilityQuality of LifeAnticonvulsantsFemaleCognitive functionNeurology (clinical)LevetiracetambusinessAntiepileptic drug030217 neurology & neurosurgerymedicine.drugEpilepsybehavior : EB
researchProduct

The safety and efficacy of add-on levetiracetam in elderly patients with focal epilepsy: A one-year observational study

2011

Abstract Purpose The long-term safety and efficacy of levetiracetam (LEV) was evaluated as add-on therapy in focal epilepsy patients ( n =491) aged at least 65 years who failed at least one monotherapy. Methods Patients ( n =491) with focal epilepsy treated with at least one antiepileptic drug in monotherapy with insufficient seizure control were included in this prospective open-label study. The recommended LEV dose range was 1000–3000mgperday. Follow-up visits were done approximately after 3, 6 and 12 months. Safety and efficacy was analysed based on all patients who received LEV (safety population, n =491) and all patients who were seen at all visits and completed the trial (per protocol…

MalePediatricsmedicine.medical_specialtyLevetiracetamEfficacyPopulationClinical NeurologyEpilepsyPharmacotherapyElderlySeizure controlmedicineHumanseducationAdverse effectAgedAged 80 and overeducation.field_of_studyEpilepsybusiness.industryGeneral Medicinemedicine.diseasePiracetamClinical trialTreatmentNeurologyAnesthesiaAnticonvulsantsDrug Therapy CombinationFemaleObservational studyEpilepsies PartialNeurology (clinical)LevetiracetamSafetybusinessmedicine.drugSeizure
researchProduct

Short-Term Neurodevelopmental Outcome in Term Neonates Treated with Phenobarbital versus Levetiracetam: A Single-Center Experience

2019

Background. Phenobarbital (PB) has been traditionally used as the first-line treatment for neonatal seizures. More recently, levetiracetam (LEV) has been increasingly used as a promising newer antiepileptic medication for treatment of seizures in neonates. Objectives. The aim of our study was to compare the effect of PB vs. LEV on short-term neurodevelopmental outcome in infants treated for neonatal seizures. Method. This randomized, one-blind prospective study was conducted on term neonates admitted to the Neonatal Intensive Care Unit of S. Bambino Hospital, University Hospital “Policlinico-Vittorio Emanuele,” Catania, Italy, from February 2016 to February 2018. Thirty term neonates with s…

MalePediatricsmedicine.medical_specialtyNeonatal intensive care unitLevetiracetamArticle Subjectneonatal seizures levetiracetam neurodevelopmental outcomemedicine.medical_treatmentneonatal seizuresNeurological examinationNeurosciences. Biological psychiatry. NeuropsychiatrySingle CenterNO03 medical and health sciences0302 clinical medicineSeizures030225 pediatricsmedicineHumansProspective StudiesProspective cohort studymedicine.diagnostic_testbusiness.industryInfant NewbornAnticonvulsants Treatment Outcome Infant Newborn Italy Levetiracetam Neurodevelopmental Disorders Phenobarbital SeizuresInfantPhenobarbital; neonatal seizures; LevetiracetamGeneral MedicineTerm neonatesNewbornNeuropsychology and Physiological PsychologyAnticonvulsantTreatment OutcomeNeurologyItalyNeurodevelopmental DisordersPhenobarbitalClinical StudyPhenobarbitalFemaleAnticonvulsantsNeurology (clinical)Levetiracetambusiness030217 neurology & neurosurgerymedicine.drugRC321-571Behavioural Neurology
researchProduct

Cognitive-behavioral screening in elderly patients with new-onset epilepsy before treatment

2014

Objectives Cognitive comorbidity at epilepsy onset reflects disease severity and provides a baseline estimate of reserve capacities with regard to the effects of epilepsy and its treatment. Given the high incidence of epilepsy at an older age, this study analyzed objective and subjective cognition as well as quality of life in elderly patients with new-onset focal epilepsy before initiation of anti-epileptic treatment. Materials and methods A total of 257 untreated patients (60–95 years of age) with new-onset epilepsy underwent objective assessment of executive function (EpiTrack) and performed subjective ratings of cognition (Portland Neurotoxicity Scale) and quality of life (QoL; QOLIE-31…

MalePediatricsmedicine.medical_specialtymedia_common.quotation_subjectComorbidityExecutive FunctionEpilepsyDouble-Blind MethodmedicineHumansAgedmedia_commonAged 80 and overEpilepsyIncidenceNeuropsychologyCognitionGeneral MedicineMiddle AgedExecutive functionsmedicine.diseaseComorbidityNeurologyQuality of LifeEtiologyPhysical therapyAnticonvulsantsFemaleNeurology (clinical)Cognition DisordersPsychologyBody mass indexVigilance (psychology)Acta Neurologica Scandinavica
researchProduct

Comparison of the effects of valproate, ethosuximide, phenytoin, and pentobarbital on cerebral energy metabolism in the rat.

1987

The acute effects of valproate (200 and 400 mg/kg), ethosuximide (200 and 400 mg/kg), phenytoin (25 and 50 mg/kg), and pentobarbital (30 and 60 mg/kg) on cerebral energy metabolism of rats were studied by measuring the cerebral content of energy metabolites and by evaluating the rate of metabolite utilization following decapitation. The treatments did not affect the levels of phosphocreatine (PCr), ATP, ADP, and AMP, but did enhance the glycogen or glucose stores. Pentobarbital induced a decrease in lactate, whereas valproate led to a decrease in pyruvate and an increase in lactate. Calculation of the metabolite fluxes after decapitation showed that all treatments delayed the rate of ATP ut…

MalePentobarbitalmedicine.medical_specialtyMetabolitemedicine.medical_treatmentPhosphocreatinechemistry.chemical_compoundAdenine nucleotideInternal medicinemedicineAnimalsGlycolysisPentobarbitalEpilepsyGlycogenAdenine NucleotidesValproic AcidBrainRats Inbred StrainsRatsEthosuximideAnticonvulsantEndocrinologyNeurologychemistryPhenytoinEthosuximideNeurology (clinical)Energy Metabolismmedicine.drugEpilepsia
researchProduct

Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortalit…

2021

Background: Sustainable Development Goal 3.2 has targeted elimination of preventable child mortality, reduction of neonatal death to less than 12 per 1000 livebirths, and reduction of death of children younger than 5 years to less than 25 per 1000 livebirths, for each country by 2030. To understand current rates, recent trends, and potential trajectories of child mortality for the next decade, we present the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 findings for all-cause mortality and cause-specific mortality in children younger than 5 years of age, with multiple scenarios for child mortality in 2030 that include the consideration of potential effects of COVID-…

MalePerinatal careNewborn careSTILLBIRTHSRJ101UNDER-5 MORTALITYPsychological intervention010501 environmental sciencesInfant mortalityGlobal Health01 natural sciences0302 clinical medicineRA0421Cause of DeathInfant MortalityGlobal healthLife TablesHealthcare improvements030212 general & internal medicine610 Medicine & healthChildCause of Death; Child; COVID-19; Global Health; Humans; Infant; Life Tables; SARS-CoV-2; Sustainable Development11 Medical and Health SciencesCause of deathLife TableMortality rate1. No povertyPublic Health Global Health Social Medicine and EpidemiologyGeneral MedicineArticlesHälsovetenskaperSustainable DevelopmentMortality analyses3. Good healthPeer reviewChild PreschoolSDG 1 - No PovertyChild MortalityFemaleLife Sciences & BiomedicineHumanChild mortalityCOUNTRIESDEATHSInfants -- MortalitatGBD610 Medicine & health03 medical and health sciencesMedicine General & InternalSDG 3 - Good Health and Well-beingLife tablesunder-5 mortality rateGeneral & Internal MedicineHealth SciencesNeonatal deathsmedicineSYSTEMATIC ANALYSISHumans:Medicine [Science]Infants -- SalutPreschool0105 earth and related environmental sciencesScience & TechnologyInfants nadons -- Salutbusiness.industrySARS-CoV-2Infants nadons -- MortalitatINFORMInfant NewbornCOVID-19InfantNeonatal and child health ; Sustainable Development Goal 3.2 ; Global healthGBD 2019 Under-5 Mortality Collaboratorsmedicine.diseaseNewbornTRENDSInfant mortalitySustainable Development GoalChild mortalityFolkhälsovetenskap global hälsa socialmedicin och epidemiologiDeaths3121 General medicine internal medicine and other clinical medicineRGbusinessSystematic AnalysisMalariaDemography
researchProduct

Phenytoin-induced glutathione depletion in rat peripheral nerve

1995

Abstract Administration of high doses (150–250 mg/kg body weight) of phenytoin (DPH) promote a 40% decrease in glutathione (GSH) content of rat sciatic nerve. This DPH-induced GSH depletion is accompanied with an electrophysiological impairment of peripheral neuromuscular function. H7 (20 mg/kg body weight IP, 30 min prior to DPH), a protein kinase C inhibitor, was able to prevent the DPH-induced GSH depletion only at the lower DPH dose used. This same inhibitor completely prevented the electrophysiological impairment at the lower DPH dose, and only partially at the higher DPH dose used. These results confirm the hypothesis of a DPH-dependent activation of PKC (that might be triggered by, o…

MalePhenytoinAntioxidantmedicine.medical_treatmentAction PotentialsIn Vitro TechniquesPharmacologymedicine.disease_causeBiochemistryPiperazineschemistry.chemical_compound1-(5-Isoquinolinesulfonyl)-2-MethylpiperazinePhysiology (medical)polycyclic compoundsmedicineAnimalsEnzyme InhibitorsRats WistarMuscle SkeletalEvoked PotentialsProtein Kinase CProtein kinase CMotor NeuronsAnalysis of Variancetechnology industry and agricultureNeurotoxicityGlutathioneIsoquinolinesmedicine.diseaseGlutathioneSciatic NerveRatsKineticschemistryBiochemistryPhenytoinAnticonvulsantslipids (amino acids peptides and proteins)Sciatic nerveOxidative stressIntracellularmedicine.drugFree Radical Biology and Medicine
researchProduct